BNP Paribas Financial Markets’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-247,848
| Closed | -$32.7M | – | 5740 |
|
|
2025
Q1 | $32.7M | Buy |
247,848
+205,538
| +486% | +$25.6M | 0.02% | 800 |
|
|
2024
Q4 | $3.53M | Buy |
42,310
+17,387
| +70% | +$1.43M | ﹤0.01% | 2015 |
|
|
2024
Q3 | $1.82M | Sell |
24,923
-24,861
| -50% | -$1.87M | ﹤0.01% | 2099 |
|
|
2024
Q2 | $3.41M | Sell |
49,784
-15,824
| -24% | -$1.1M | ﹤0.01% | 1606 |
|
|
2024
Q1 | $4.54M | Sell |
65,608
-198,668
| -75% | -$13.7M | ﹤0.01% | 1518 |
|
|
2023
Q4 | $18.9M | Sell |
264,276
-56,612
| -18% | -$3.26M | 0.02% | 727 |
|
|
2023
Q3 | $16.7M | Buy |
320,888
+36,849
| +13% | +$2.15M | 0.02% | 678 |
|
|
2023
Q2 | $18M | Buy |
284,039
+95,623
| +51% | +$5.96M | 0.02% | 657 |
|
|
2023
Q1 | $10.2M | Buy |
188,416
+121,072
| +180% | +$5.85M | 0.01% | 888 |
|
|
2022
Q4 | $3.56M | Buy |
67,344
+13,630
| +25% | +$683K | 0.01% | 1487 |
|
|
2022
Q3 | $2.5M | Buy |
53,714
+11,090
| +26% | +$579K | ﹤0.01% | 1803 |
|
|
2022
Q2 | $2.43M | Buy |
42,624
+22,491
| +112% | +$1.28M | ﹤0.01% | 1642 |
|
|
2022
Q1 | $1.23M | Buy |
20,133
+5,189
| +35% | +$269K | ﹤0.01% | 2173 |
|
|
2021
Q4 | $782K | Buy |
14,944
+2,290
| +18% | +$96.2K | ﹤0.01% | 2757 |
|
|
2021
Q3 | $472K | Buy |
12,654
+10,006
| +378% | +$348K | ﹤0.01% | 2775 |
|
|
2021
Q2 | $108K | Sell |
2,648
-17,668
| -87% | -$653K | ﹤0.01% | 3020 |
|
|
2021
Q1 | $689K | Buy |
20,316
+7,351
| +57% | +$255K | ﹤0.01% | 2374 |
|
|
2020
Q4 | $412K | Sell |
12,965
-2,424
| -16% | -$63.7K | ﹤0.01% | 2561 |
|
|
2020
Q3 | $395K | Buy |
15,389
+11,845
| +334% | +$270K | ﹤0.01% | 2362 |
|
|
2020
Q2 | $91K | Sell |
3,544
-13,486
| -79% | -$273K | ﹤0.01% | 2807 |
|
|
2020
Q1 | $262K | Buy |
17,030
+10,797
| +173% | +$234K | ﹤0.01% | 2722 |
|
|
2019
Q4 | $214K | Sell |
6,233
-1,887
| -23% | -$22.6K | ﹤0.01% | 2927 |
|
|
2019
Q3 | $60.7K | Buy |
8,120
+2,101
| +35% | +$20.1K | ﹤0.01% | 3374 |
|
|
2019
Q2 | $78.1K | Sell |
6,019
-4,342
| -42% | -$55.7K | ﹤0.01% | 3171 |
|
|
2019
Q1 | $126K | Buy |
10,361
+9,307
| +883% | +$119K | ﹤0.01% | 2981 |
|
|
2018
Q4 | $12K | Sell |
1,054
-1,512
| -59% | -$24.4K | ﹤0.01% | 3284 |
|
|
2018
Q3 | $55.7K | Buy |
2,566
+192
| +8% | +$4.01K | ﹤0.01% | 2997 |
|
|
2018
Q2 | $41.9K | Sell |
2,374
-6,365
| -73% | -$129K | ﹤0.01% | 3198 |
|
|
2018
Q1 | $184K | Buy |
8,739
+29
| +0.3% | +$565 | ﹤0.01% | 2839 |
|
|
2017
Q4 | $126K | Buy |
8,710
+4,514
| +108% | +$69.7K | ﹤0.01% | 3184 |
|
|
2017
Q3 | $66.2K | Sell |
4,196
-243
| -5% | -$3.57K | ﹤0.01% | 2997 |
|
|
2017
Q2 | $55.1K | Buy |
4,439
+3,683
| +487% | +$42.7K | ﹤0.01% | 3139 |
|
|
2017
Q1 | $12.3K | Sell |
756
-340
| -31% | -$4.92K | ﹤0.01% | 3144 |
|
|
2016
Q4 | $16.5K | Sell |
1,096
-2,691
| -71% | -$38K | ﹤0.01% | 3260 |
|
|
2016
Q3 | $57.7K | Buy |
3,787
+2,458
| +185% | +$99.4K | ﹤0.01% | 2367 |
|
|
2016
Q2 | $51.6K | Buy |
+1,329
| New | +$47.8K | ﹤0.01% | 2299 |
|
|
2016
Q1 | – | Sell |
-4,980
| Closed | -$268K | – | 3119 |
|
|
2015
Q4 | $268K | Buy |
4,980
+459
| +10% | +$23.2K | ﹤0.01% | 1732 |
|
|
2015
Q3 | $181K | Buy |
4,521
+2,716
| +150% | +$88.6K | ﹤0.01% | 2026 |
|
|
2015
Q2 | $57.7K | Buy |
1,805
+1,407
| +354% | +$35.7K | ﹤0.01% | 2409 |
|
|
2015
Q1 | $9.5K | Buy |
+398
| New | +$8.91K | ﹤0.01% | 2780 |
|
|
2014
Q4 | – | Sell |
-1,023
| Closed | -$14K | – | 3303 |
|
|
2014
Q3 | $14K | Buy |
+1,023
| New | +$15.4K | ﹤0.01% | 3394 |
|
Other funds holding ITCI
KIM
HNB
BNP Paribas Financial Markets's ITCI Position: Q2 2025 in Review
BNP Paribas Financial Markets sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 247,848 shares — an estimated $32.7M sold.
BNP Paribas Financial Markets first reported a position in ITCI in Q3 2014 and held it in 41 quarters. The position peaked at $32.7M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- BNP Paribas Financial Markets reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 247,848 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $32.7M.
- BNP Paribas Financial Markets first reported a position in Intra-Cellular Therapies Inc. in Q3 2014 and held it in 41 quarters.
- BNP Paribas Financial Markets's Intra-Cellular Therapies Inc. position peaked at $32.7M in Q1 2025.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2025, filed 14 Aug 2025.